[PROGNOSTIC ROLE OF NF-κB EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUPS]

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) prognosis varies by subtype, with germinal center B-cell (GCB) phenotype generally having a better outlook than activated B-cell (ABC) or type 3 phenotypes.
• Nuclear factor-kappa B (NF-κB) signaling is implicated in ABC and type 3 DLBCL, while GCB DLBCL is associated with REL amplifications.

Purpose of the Study:

• To investigate the prognostic significance of nuclear factor-kappa B (NF-κB) expression in different subtypes of diffuse large B-cell lymphoma (DLBCL).
• To determine if NF-κB localization (nuclear vs. cytoplasmic) correlates with patient survival and clinical parameters in DLBCL.

Main Methods:

• Immunohistochemical analysis of CD10, BCL6, and MUM1 to classify 99 DLBCL patients into GCB, ABC, and type 3 subgroups.
• Assessment of NF-κB expression in both the nucleus and cytoplasm of tumor cells.
• Correlation of NF-κB expression patterns with clinical data and patient survival outcomes.

Main Results:

• Cytoplasmic NF-κB expression was significantly associated with poorer survival across all DLBCL subgroups.
• GCB phenotype DLBCL patients with negative nuclear NF-κB expression demonstrated significantly better survival compared to those with positive nuclear NF-κB.
• No significant association was found between nuclear NF-κB accumulation and clinical parameters like age, sex, disease stage, or therapy (e.g., R-CHOP).

Conclusions:

• Nuclear and cytoplasmic NF-κB expression may serve as independent prognostic factors in DLBCL, potentially explaining stratified risks in combination with GCB/non-GCB phenotypes.
• NF-κB activity appears critical in all DLBCL subgroups, suggesting it as a promising molecular target for novel therapeutic strategies.